Table 2.

Changes in bodyweight and metabolic factors between baseline and week 12

	Liraglutide 0.6 mg (n = 28)		Liraglutide 1.2 mg (n = 18)		Liraglutide 0.6 mg vs liraglutide 1.2 mg
	Change in 12 weeks	P‐value	Change in 12 weeks	P‐value
Change in bodyweight
Percentage of bodyweight (%)	−6.4		−5.6		0.710
Kilograms of bodyweight	−7.0	<0.001*	−6.0	<0.001*	0.830
Loss of >5% of bodyweight, n (%)	9 (32.1)		8 (44.4)		0.474
Loss of >10% of bodyweight, n (%)	4 (14.8)		4 (22.2)		0.488
BMI (kg/m2)	−1.8	<0.001*	−2.0	0.002*	0.599
Waist circumference (cm)	−4.2	0.000*	−6.4	0.008*	0.326
Fasting glucose (mg/dL)	0.9	0.794	−8.2	0.286	0.043**
Glycated hemoglobin (%)	−0.5	0.005*	−0.3	0.017*	0.089
Insulin (μU/mL)	−1.3	0.463	−5.4	0.237	0.568
HOMA‐IR	−0.2	0.463	−1.7	0.128	0.253
Insulin : glucose ratio	−0.02	0.500	−0.02	0.893	0.854
Cholesterol (mg/dL)
Total	−5.6	0.538	−26.0	0.289	0.506
HDL cholesterol	0.8	0.569	−0.6	0.553	0.674
LDL cholesterol	−2.4	0.485	2.2	0.875	0.710
VLDL cholesterol	−1.0	0.182	−1.3	0.735	0.463
Non‐HDL cholesterol	−13.3	0.102	5.2	0.859	0.350
Triglycerides (mg/dL)	−9.8	0.170	−60.3	0.754	0.147
ALT (mg/dL)	−25.2	0.001*	−25.8	0.136	0.388
HsCRP (mg/dL)	−2.34	0.093	−5.90	0.674	0.345
Uric acid (mg/dL)	−1.4	0.002*	−0.4	0.041*	0.147

Values are presented as the mean or n (%). The Mann–Whitney U‐test was used for continuous variables; the χ²‐test was used for categorical variables; the Wilcoxon signed‐rank test was used to compare bodyweight and metabolic factor between baseline and week 12.

^* P value <0.05 when comparing baseline metabolic factors with baseline.

^** P value <0.05 when comparing metabolic factors between liraglutide 0.6 mg and liraglutide 1.2 mg. ALT, alanine aminotransferase; BMI, body mass index; HDL, high‐density lipoprotein; HOMA‐IR, homeostatic model assessment for insulin resistance; HsCRP, high‐sensitivity C‐reactive protein; LDL, low‐density lipoprotein; VLDL, very low‐density lipoprotein.